Fexofenadine for active rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 1/2 study tests whether fexofenadine (an allergy medicine) can improve symptoms and inflammation in people with active rheumatoid arthritis. Participants may be assigned to different treatment groups, and the study looks at safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active rheumatoid arthritis that is moderate to severe (based on a doctor’s scoring of 28 joints).
- You’re between 18 and 60 years old.
- You’ve been on disease-modifying anti-rheumatic drugs (DMARDs), and you are not using cytokine (biologic) inhibitor medicines.
- You can sign consent and are willing to be assigned to any study treatment group (randomization).
- You cannot have previously used biological DMARDs (biologic medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding roflumilast, a new medication, to your current rheumatoid arthritis treatment can help reduce joint inflammation and improve your symptoms. You would take it alongside methotrexate, a common RA medication you may already be using.
This trial studies whether certain medicines can improve how active rheumatoid arthritis is. If you have rheumatoid arthritis and do not have significant liver or kidney problems, you may be able to join.
This study tests whether desloratadine, an allergy medication, can help reduce rheumatoid arthritis symptoms when added to your current treatments. Researchers want to see if it reduces joint swelling and pain alongside your existing therapy.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.